Tiziana Life Sciences PLC (NASDAQ:TLSA, LSE:TILS, OTC:TIZAF) is making excellent progress in its nasal foralumab extension Multiple Sclerosis (MS) trial, Proactive Research Analyst John Savin told Proactive's Stephen Gunnion.
Savin released a 2022 update on the US biotech research company, which shifted its listing to the Nasdaq in the US last year.
Savin telling Proactive if trials progress well this year, its portfolio of products will create good underlying value for shareholders.